Filippo Montemurro
Università degli Studi di Torino
H-index: 46
Europe-Italy
Top articles of Filippo Montemurro
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Abstract PO4-04-05: HER2 immunohistochemistry (IHC) expression in HER2-positive (HER2-pos) metastatic breast cancer (mBC): clinical and prognostic differences between IHC 2+ … | Cancer Research | Arianna Dri Eva Blondeaux Claudia Bighin Simona Gasparro Stefania Russo | 2024/5/2 |
Abstract PO1-03-02: Impact of Body Mass Index (BMI) on the efficacy of different adjuvant chemotherapy schedules in patients with breast cancer: analysis from the randomized … | Cancer Research | Francesca Poggio Eva Blondeaux Marco Tagliamento Marta Perachino Simone Nardin | 2024/5/2 |
Gender minorities in breast cancer–Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patients | The Breast | Federica Miglietta Letizia Pontolillo Carmine De Angelis Roberta Caputo Monica Marino | 2024/6/1 |
Mitotic Spindle Assembly and Genomic Stability in Breast Cancer Require PI3K-C2a Scaffolding Function Federico Gulluni, 1, 14 Miriam Martini, 1, 14,* Maria Chiara De Santis, 1 … | Mara Compagno Sara Sigismund Filippo Montemurro Marcus Thelen Fan Fan | 2024/4/26 | |
Abstract PO3-06-01: Factors associated with first-and second-line attrition among metastatic breast cancer patients | Cancer Research | Eva Blondeaux Luca Boni Giovanna Chilà Arianna Dri Roberta Caputo | 2024/5/2 |
Epidemiology, Pathology, Diagnosis, Prevention, and Management of Unknown Primary Cancer | Gastrointestinal Oncology‐A Critical Multidisciplinary Team Approach 2e | Alicia‐Marie Conway Claire Mitchell Aidalena Abidin Izaak Jankowski Elena Geuna | 2024/1/23 |
Abstract PS11-01: Brain metastases in metastatic breast cancer: prevalence per line of treatment and cumulative incidence in a cohort of 18075 real-world patients | Cancer Research | Sarah Sammons Jose Leone Thibaut Sanglier Peter Lambert Filippo Montemurro | 2024/5/2 |
Toxicity profile of antibody-drug conjugates in breast cancer: Practical considerations | Andrea D’Arienzo Annarita Verrazzo Martina Pagliuca Fabiana Napolitano Sara Parola | 2023/8/1 | |
SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials | Clinical Cancer Research | Benedetta Conte Luca Boni Giancarlo Bisagni Antonio Durando Giovanni Sanna | 2023/12/15 |
Dysgeusia in patients with breast cancer treated with chemotherapy—a narrative review | Marianna Pellegrini Fabio Dario Merlo Elena Agnello Taira Monge Andrea Devecchi | 2023/1/1 | |
De-escalation in low-risk, HER2-positive breast cancer | The Lancet Oncology | Elena Geuna Giuseppe Curigliano Filippo Montemurro | 2023/3/1 |
Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual … | Eclinicalmedicine | Matteo Lambertini Eva Blondeaux Giancarlo Bisagni Silvia Mura Sabino De Placido | 2023/5/1 |
199P Correlation of circulating tumor DNA (ctDNA) or thymidine kinase activity (TKa) dynamic patterns with tumor response in patients (pts) with hormone receptor (HR)+ human … | ESMO Open | G Arpino G Bianchini L Malorni R Caputo A Zambelli | 2023/5/1 |
Estrogen deprivation effects of endocrine therapy in breast cancer patients: Incidence, management and outcome | Linda Cucciniello Giovanna Garufi Rossana Di Rienzo Claudia Martinelli Giuliana Pavone | 2023/9/7 | |
Discontinuation rate and serious adverse events of chemoimmunotherapy as neoadjuvant treatment for triple-negative breast cancer: a systematic review and meta-analysis | A Rizzo FM Schipilliti F Di Costanzo S Acquafredda G Arpino | 2023/12/1 | |
Correction to: Real-world histopathological approach to malignancy of undefined primary origin (MUO) to diagnose cancers of unknown primary (CUPs) | Virchows Archiv | Alberto Pisacane Eliano Cascardi Enrico Berrino Alessio Polidori Ivana Sarotto | 2023 |
Real-world histopathological approach to malignancy of undefined primary origin (MUO) to diagnose cancers of unknown primary (CUPs) | Virchows Archiv | Alberto Pisacane Eliano Cascardi Enrico Berrino Alessio Polidori Ivana Sarotto | 2023/3 |
Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: A systematic literature … | Volkmar Mueller Rupert Bartsch Nancy U Lin Filippo Montemurro Mark D Pegram | 2023/4/1 | |
Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer | npj Breast Cancer | Luca Licata Giulia Viale Mario Giuliano Giuseppe Curigliano Mariana Chavez-MacGregor | 2023/6/8 |
Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial | Tumori Journal | Benedetta Conte Filippo Montemurro Alessia Levaggi Eva Blondeaux Chiara Molinelli | 2023/2 |
